0000000001024775

AUTHOR

S Colafrancesco

showing 2 related works from this author

ESTREMO/WFXRT: Extreme phySics in the TRansient and Evolving COsmos

2006

We present a mission designed to address two main themes of the ESA Cosmic Vision Programme: the Evolution of the Universe and its Violent phenomena. ESTREMO/WFXRT is based on innovative instrumental and observational approaches, out of the mainstream of observatories of progressively increasing area, i.e.: Observing with fast reaction transient sources, like GRB, at their brightest levels, thus allowing high resolution spectroscopy. Observing and surveying through a X-ray telescope with a wide field of view and with high sensitivity extended sources, like cluster and Warm Hot Intragalactic Medium (WHIM). ESTREMO/WFXRT will rely on two cosmological probes: GRB and large scale X-ray structur…

PhysicsCosmic VisionAstrophysics::High Energy Astrophysical Phenomenamedia_common.quotation_subjectDark matterAstrophysics::Instrumentation and Methods for AstrophysicsAstronomyX-ray telescopeAstrophysics::Cosmology and Extragalactic AstrophysicsAstrophysicsCosmologyUniverselaw.inventionTelescopeSettore FIS/05 - Astronomia e AstrofisicalawX-ray instruments Cosmology Gamma-Ray Bursts Clusters of galaxiesDark energyGamma-ray burstmedia_common
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct